Cardiff Oncology Q1 2024 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $205.000K Beat $55.000K Estimate
Cardiff Oncology Q1 2024 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $205.000K Beat $55.000K Estimate
加的夫肿瘤学2024年第一季度GAAP每股收益美元（0.22美元）超过预期（0.25美元），销售额20.5万美元超过预期的5.5万美元
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 12 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $205.000 thousand which beat the analyst consensus estimate of $55.000 thousand by 272.73 percent. This is a 146.99 percent increase over sales of $83.000 thousand the same period last year.
加的夫肿瘤学（纳斯达克股票代码：CRDF）公布的季度亏损为每股0.22美元，比分析师普遍预期的0.25美元（0.25美元）高出12％。这比去年同期每股亏损0.25美元（0.25美元）增长了12％。该公司公布的季度销售额为20.5万美元，比分析师普遍预期的55,000美元高出272.73％。这比去年同期的83,000美元销售额增长了146.99％。